These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Efficacy of angiotensin receptor neprilysin inhibitor in Asian patients with refractory hypertension. Li W; Gong M; Yu Q; Liu R; Chen K; Lv W; Yao F; Xu Z; Xu Y; Song W; Jiang Y J Clin Hypertens (Greenwich); 2022 Apr; 24(4):449-456. PubMed ID: 35253964 [TBL] [Abstract][Full Text] [Related]
11. Dual Angiotensin Receptor and Neprilysin Inhibition with Sacubitril/Valsartan in Chronic Systolic Heart Failure: Understanding the New PARADIGM. Lillyblad MP Ann Pharmacother; 2015 Nov; 49(11):1237-51. PubMed ID: 26175499 [TBL] [Abstract][Full Text] [Related]
12. Angioedema Spotlight: A Closer Examination of Sacubitril/Valsartan Safety Results. Owens RE; Oliphant CS J Am Board Fam Med; 2017; 30(4):556-557. PubMed ID: 28720639 [TBL] [Abstract][Full Text] [Related]
13. Sacubitril/Valsartan: potential treatment for paediatric heart failure. Das BB; Scholl F; Vandale B; Chrisant M Cardiol Young; 2018 Sep; 28(9):1077-1081. PubMed ID: 29979147 [TBL] [Abstract][Full Text] [Related]
14. Sacubitril/Valsartan: Neprilysin Inhibition 5 Years After PARADIGM-HF. Docherty KF; Vaduganathan M; Solomon SD; McMurray JJV JACC Heart Fail; 2020 Oct; 8(10):800-810. PubMed ID: 33004114 [TBL] [Abstract][Full Text] [Related]
15. Angiotensin Receptor Neprilysin Inhibitor Attenuates Myocardial Remodeling and Improves Infarct Perfusion in Experimental Heart Failure. Pfau D; Thorn SL; Zhang J; Mikush N; Renaud JM; Klein R; deKemp RA; Wu X; Hu X; Sinusas AJ; Young LH; Tirziu D Sci Rep; 2019 Apr; 9(1):5791. PubMed ID: 30962467 [TBL] [Abstract][Full Text] [Related]
17. Sacubitril/valsartan and B-type natriuretic peptide value: recalculating route. Abellas-Sequeiros M; Del Prado Díaz S; Del Rey JM; Alonso-Salinas GL; Zamorano JL Eur J Heart Fail; 2020 Jan; 22(1):162-163. PubMed ID: 31410947 [No Abstract] [Full Text] [Related]
18. Activation of GLP-1 receptor signalling by sacubitril/valsartan: Implications for patients with poor glycaemic control. Mahtani K; Patel B; Wang B; Barron A Int J Cardiol; 2022 Nov; 367():81-89. PubMed ID: 35944765 [TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics After Single Ascending Dose, Food Effect, and Safety of Sacubitril/Valsartan (LCZ696), an Angiotensin Receptor and Neprilysin Inhibitor, in Healthy Japanese Subjects. Akahori M; Ayalasomayajula S; Langenickel T; Pal P; Zhou W; Sunkara G Eur J Drug Metab Pharmacokinet; 2017 Jun; 42(3):407-416. PubMed ID: 27324506 [TBL] [Abstract][Full Text] [Related]